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Abstract
Lambda Red recombineering is a powerful technique for making targeted genetic changes in bacteria. However, many
applications are limited by the frequency of recombination. Previous studies have suggested that endogenous nucleases
may hinder recombination by degrading the exogenous DNA used for recombineering. In this work, we identify ExoVII as a
nuclease which degrades the ends of single-stranded DNA (ssDNA) oligonucleotides and double-stranded DNA (dsDNA)
cassettes. Removing this nuclease improves both recombination frequency and the inheritance of mutations at the 39 ends
of ssDNA and dsDNA. Extending this approach, we show that removing a set of five exonucleases (RecJ, ExoI, ExoVII, ExoX,
and Lambda Exo) substantially improves the performance of co-selection multiplex automatable genome engineering (CoS-
MAGE). In a given round of CoS-MAGE with ten ssDNA oligonucleotides, the five nuclease knockout strain has on average
46% more alleles converted per clone, 200% more clones with five or more allele conversions, and 35% fewer clones
without any allele conversions. Finally, we use these nuclease knockout strains to investigate and clarify the effects of
oligonucleotide phosphorothioation on recombination frequency. The results described in this work provide further
mechanistic insight into recombineering, and substantially improve recombineering performance.
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Introduction
Lambda Red recombination (‘‘recombineering’’) has emerged
as a useful tool in genetics and molecular biology, facilitating the
precise generation of insertions, deletions, and point mutations at
loci specified by flanking homology regions of as little as 35 bp [1].
Lambda Red, as well as the similar RecET system [2], is capable
of modifying Escherichia coli chromosomal [2,3], plasmid [2,4], and
BAC [5,6,7,8] targets using either dsDNA cassettes [2,3] or
ssDNA oligonucleotides [9,10]. Both strategies have been used
toward a broad array of powerful applications. Recombineering
with dsDNA cassettes has been used to insert heterologous genes
[11] and pathways [12] onto the E. coli chromosome for use in
metabolic engineering and other efforts. Additionally, dsDNA
recombineering has been applied to facilitate cloning and
subcloning [13,14], and to replace endogenous genes [15],
enabling the creation of a library of single-gene knockout E. coli
strains [16] and the generation of a strain of E. coli with 15% of its
genome removed [17]. Recent applications of oligonucleotide
recombineering have leveraged the ability of Lambda Red to
simultaneously recombine multiple oligos (i.e. ‘‘Multiplex Auto-
matable Genome Engineering’’, or ‘‘MAGE’’) [18]. This tech-
nique has been used to diversify and rapidly optimize the pathway
coding for the biosynthesis of the small molecule lycopene [18], to
engineer promoters [19], and to change all E. coli amber (TAG)
stop codons into ochre (TAA) stop codons [20].
However, despite the versatility and power of Lambda Red
recombineering, many applications are limited by the frequency of
recombination. The low recombination frequency of gene
insertion (,5610
24 recombinants per viable cell) [3] necessitates
the linkage of inserted genes to selectable markers, preventing one-
step, markerless gene insertion and the simultaneous insertion of
multiple cassettes. Similarly, only a limited number of simulta-
neous mutations can reliably be generated in a given cycle of
MAGE [20], thus constraining the degree to which a genome can
conveniently be reengineered. Emerging mechanistic knowledge of
Lambda Red recombination may identify strategies for overcom-
ing these barriers.
Recently, it has been shown that the mechanism for Lambda
Red dsDNA recombination proceeds by a similar process as
oligonucleotide recombination [21,22]. Three phage Lambda-
derived proteins are required to mediate dsDNA recombination.
The first, Gam, inhibits the endogenous RecBCD and SbcCD
nucleases [23], which would otherwise degrade the exogenous
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Exonuclease (Exo), degrades one of the two strands in its entirety,
leaving behind a full-length strand of ssDNA [21,22]. The third
protein, Beta, then binds to this ssDNA and catalyzes its annealing
to the lagging strand of the replication fork, where it is
incorporated into the newly synthesized strand as part of an
Okazaki fragment [21,22]. Given this mechanism, recombination
predominantly occurs when Lambda Exo degrades the leading-
targeting strand of dsDNA, leaving behind the lagging-targeting
strand for recombination at the replication fork. The final step of
Beta-catalyzed annealing and incorporation as an Okazaki
fragment is analogous to the accepted mechanism for Red-
mediated oligonucleotide recombination, which requires only the
Beta recombinase [24].
Mechanistic insight into Lambda Red recombination has
already elucidated several means of improving recombination
frequency. For instance, clarifying the mechanism of dsDNA
recombination led to the insight that using phosphorothioate
bonds to protect the lagging-targeting dsDNA strand would
improve recombination frequency, while protecting the leading-
targeting strand would not [21,22]. Similarly, singleplex oligonu-
cleotide recombination frequency was optimized to ,30% from
initial frequencies of ,0.2% by targeting oligos to the lagging
strand of the replication fork [25], removing the mismatch repair
protein MutS [26] or evading its action via modified bases [27],
minimizing internal oligo secondary structure [18], optimizing
homology lengths [18], and introducing phosphorothioate bonds
to prevent nuclease degradation of oligonucleotides [18]. Recently,
the frequency of multiplex oligonucleotide recombination has also
been greatly improved by directing an oligo to repair a mutated
antibiotic resistance gene in the vicinity of the loci targeted by the
other recombineering oligos [28]. Thus, co-selection MAGE (CoS-
MAGE) enriches for cells with high levels of recombination near
the corrected selectable marker, and increases recombination
frequencies significantly.
In this work, we focus on removing endogenous nuclease
enzymes as a means of further improving recombineering
properties. Many lines of evidence suggest that endogenous
nucleases limit recombination. As discussed previously, using
phosphorothioate bonds to protect oligonucleotides [18] and
dsDNA cassettes [21,22] has been shown to improve recombina-
tion frequency, suggesting that endogenous nuclease degradation
can render these cassettes non-recombinogenic. This is bolstered
by the recent observation that knocking out four potent ssDNA
exonucleases improves singleplex oligonucleotide recombination
frequency when low concentrations of oligos are used [29].
Furthermore, it has been shown that mutations located near the
ends of an oligonucleotide [27] or dsDNA cassette [21] are
inherited less often than mutations located closer to the interior of
the oligo or cassette. This further implies degradation of
oligonucleotides and dsDNA, and suggests that this nuclease
processing prevents the inheritance of mutations along the full
length of a cassette. We reasoned that by inactivating certain
endogenous nucleases, we could improve recombination frequency
and the preservation of mutations encoded at the ends of cassettes.
In this work, we first investigate the nuclease processing of dsDNA,
and identify ExoVII as a key nuclease which degrades the ends of
dsDNA cassettes. Removing this nuclease facilitates preservation
of mutations on the ends of dsDNA cassettes as well as ssDNA
oligos. This discovery led us to investigate nuclease processing in
the context of MAGE, and to identify a set of nucleases capable of
degrading recombineering oligonucleotides. Removal of these
nucleases provides for substantial improvement of recombination
frequency, thereby facilitating greater diversity generation and the
creation of more simultaneous mutations.
Results
Using Phosphorothioated Cassettes to Investigate
Nuclease Processing of dsDNA
Our observations regarding the recombination frequencies of
phosphorothioated dsDNA cassettes [21] led us to investigate the
possibility that the ends of cassettes are routinely degraded by
endogenous nucleases. Phosphorothioate (PT) bonds have been
reported to block Lambda Exo from degrading dsDNA cassettes
[30], an observation that we have confirmed in an in vitro
experiment using recombinant Lambda Exo (Figure 1A–B).
Despite this, placing PT bonds on both 59 ends of a dsDNA
cassette does not decrease (and actually enhances) the recombi-
nation frequency of that cassette in vivo [21,22]. This is surprising,
given that according to the current mechanism, Lambda Exo must
bind to a 59 dsDNA end and degrade that strand in order for
recombination to occur [21,22]. Prior mechanisms for Red-
mediated dsDNA recombination [24,31] have similar implica-
tions, requiring Lambda Exo to degrade both 59 ends of a dsDNA
cassette. It is not immediately apparent how a cassette with both 59
ends phosphorothioated could be processed by Lambda Exo and
undergo recombination. It is possible that Lambda Exo behaves
differently in vivo than in vitro (e.g. due to the presence of protein
partners or cofactors), and is able to degrade phosphorothioate
bonds in a cellular context. Alternatively, an endogenous E. coli
nuclease may degrade the 59 PT bonds on one or both strands,
thereby allowing Lambda Exo to degrade the remainder of the
strand and generate the ssDNA recombination intermediate.
To investigate this, we generated a set of seven variably
phosphorothioated (VPT) lacZ::kanR dsDNA insertion cassettes
(Figure 1A) with four PT bonds located either terminally, at the 59
end of the cassette, or internally, between the homology and
heterology regions. These PT bonds were placed on neither
strand, on the lagging-targeting strand only, on the leading-
targeting strand only, or on both strands. These constructs were
recombined into EcNR2 (strain genotypes given in Table 1), and
recombination frequencies were calculated by dividing the number
of kanamycin-resistant recombinant cfu (colony forming units) by
the number of total cfu. Results are shown in Figure 1C and in
Table S2.
Several trends are apparent. Relative to unmodified dsDNA
(VPT1), terminal PT bonds are beneficial when placed on the
lagging-targeting strand (VPT2), as they protect the recombino-
genic strand from being degraded. Conversely, terminal PT bonds
are slightly detrimental when located on the leading-targeting
strand (VPT3), as they interfere with the ability of Lambda Exo to
degrade that strand and generate the lagging-targeting ssDNA
intermediate. The cassette with terminal PTs placed on both
strands (VPT4) is roughly equivalent (1.23 times more recombi-
nogenic, as shown in Figure 1F) to unmodified dsDNA (VPT1),
presumably due to a cancellation of the two effects discussed
above.
Internally located PT bonds, however, show a much more
striking effect. When on the lagging-targeting strand only (VPT5),
they do not decrease recombination frequency. However, inter-
nally located PT bonds on the leading-targeting strand (VPT6 and
VPT7) are highly detrimental to recombination frequency. These
cassettes have substantially lower recombination frequencies than
the corresponding terminally phosphorothioated cassettes (VPT3
and VPT4, respectively), with a VPT4:VPT7 ratio of 12.3
(Figure 1G) and a VPT3:VPT6 ratio of 4.9. This suggests that
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bonds at blocking Lambda Exo from degrading the leading-
targeting strand and generating the ssDNA recombination
intermediate. Thus, it is unlikely that Lambda Exo can indepen-
dently degrade phosphorothioates in vivo; rather, it appears that an
endogenous nuclease is able to cleave terminally located PT
bonds, thereby allowing Lambda Exo to degrade the remainder of
the strand. Internally located PT bonds are not directly accessible
to this endogenous nuclease, and/or cannot be removed without
rendering the cassette non-recombinogenic due to the degradation
of one of its homology regions. Thus, blocking the leading-
targeting strand with internal PT bonds has a uniquely detrimental
effect on recombination frequency.
These results suggest a strategy for identifying the nuclease(s)
responsible for degrading the phosphorothioated ends of dsDNA
cassettes: inactivate candidate nucleases, and then compare the
recombination frequencies of unmodified dsDNA (VPT1) and
dsDNA with terminal PT bonds on both strands (VPT4). If the
nuclease(s) responsible for pruning terminal PT bonds are still
present, then VPT4 will have a recombination frequency that is
roughly equal to that of VPT1 (VPT4:VPT1 < 1.0, as in EcNR2).
However, if the nuclease(s) have been removed, the strain will no
longer be able to degrade the phosphorothioate bonds on the ends
of the VPT4 dsDNA. Thus, the recombination frequency of VPT4
will drop well below that of VPT1 (VPT4:VPT1,,1), as Lambda
Exo can no longer generate the ssDNA recombination interme-
diate.
We first tested VPT1 and VPT4 in a strain lacking Endonu-
clease I (endA), a potent periplasmic endonuclease capable of
degrading dsDNA [32]. This resulted in a VPT4:VPT1 ratio of
1.55, similar to that observed for the EcNR2 strain (Table 2).
Thus, Endonuclease I is not responsible for degrading the
phosphorothioated ends of dsDNA cassettes.
We next tested a strain which lacked the four primary [33] E.
coli ssDNA exonucleases – recJ/RecJ, [34] xonA/ExoI, [35] xseA/
ExoVII, [36] and exoX/ExoX [37]. This strain (EcNR2.recJ
2,xo-
nA
2,xseA
2,exoX
2, or ‘‘nuc4
2’’; Table 1) demonstrated a
VPT4:VPT1 ratio of 0.09, far lower than that of EcNR2
(Table 2). Thus, recombination frequency data for the full VPT
series was collected in this strain (Figure 1D). These data show a
strikingly different trend than that observed for EcNR2. The
recombination frequency of VPT4 is indeed far lower than that of
VPT1 (Figure 1F). Additionally, terminal PT bonds on the
leading-targeting strand are just as detrimental to recombination
frequency as internal PT bonds (VPT3:VPT6=1.41;
VPT4:VPT7=0.75, Figure 1G). Because constructs with terminal
PT bonds on the leading-targeting strand are minimally
recombinogenic in nuc4
2, this suggests that these constructs can
Figure 1. Investigating Nuclease Processing with Variably Phosphorothioated Cassettes. A) Diagram of the variably phosphorothioated
(VPT) cassette series. Homology arms to lacZ are shown in blue, and the inserted heterologous kanR gene is shown in gold; the lagging-targeting
strand is represented as the top strand, and the leading-targeting strand is represented as the bottom strand. The red asterisk indicates the presence
of 4 consecutive phosphorotiohate bonds. B) In vitro Lambda Exo digestion of non-phosphorothioated (VPT1, left), single end phosphorothioated
(VPT2, center), and dually phosphorothioated (VPT4, right) dsDNA cassettes. Samples were digested with no enzyme (lanes 1, 5, & 9) and tenfold-
increasing amounts of enzyme, from left to right. The bottom band is dsDNA, and the top band is the ssDNA product after Lambda Exo degrades one
of the two strands. PAGE analysis confirms that dually phosphorothioated cassettes are protected from degradation. C–E) Recombination
frequencies for the VPT cassette series in EcNR2 (C), nuc4
2 (D), and EcNR2.xseA
2 (E). Insertion frequencies were measured as the number of
kanamycin resistant recombinants over the total number of cfu (as plated on non-selective media). These data are presented as the mean with the
error bars as standard deviation; n=3 for EcNR2 and EcNR2.xseA
2, and n=2 for nuc4
2. Numerical data are shown in Table S2. F& G) Cassette
insertion frequencies were measured in technical replicates for EcNR2, nuc4
2, and EcNR2.xseA
2. Data in F) & G) are presented as the mean with the
standard error of the mean. The ratio between VPT4 and VPT1 (F) indicates a strain’s ability to recombine cassettes with terminal PT bonds preventing
the direct action of Lambda Exo. The ratio between VPT4 and VPT7 (G) indicates whether a strain is more able to process terminal PT bonds (VPT4) in
comparison with internal PT bonds (VPT7).
doi:10.1371/journal.pone.0044638.g001
Table 1. Genotypes of Abbreviated Strains.
Strain Name Strain Genotype
EcNR2 Escherichia coli MG1655 DmutS::cat D(ybhB-bioAB)::[lcI857
N(cro-ea59)::tetR-bla]
nuc4
2 EcNR2.xonA
2,recJ
2,xseA
2,exoX
2
nuc5
2 EcNR2.xonA
2,recJ
2,xseA
2,exoX
2,reda
2
Genotypes of all abbreviated strains are presented here for clarity.
doi:10.1371/journal.pone.0044638.t001
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nuclease(s) capable of cleaving off these PT bonds is/are absent in
this strain. Residual recombinants for such cassettes may be due to
a limited ability of Lambda Exo to degrade PT bonds, or to slight
nuclease activity that is still present.
To identify which nuclease(s) is/are responsible for cleaving
terminal PT bonds, four strains were generated, each of which
restored one of the four nucleases removed in nuc4
2 (i.e. three
of the four nucleases were inactivated in these strains). VPT1
and VPT4 were recombined into these strains, and the
VPT4:VPT1 ratio of recombinants was measured (Table 2).
One of the four strains (EcNR2.recJ
2,xonA
2,xseA
2) was surpris-
ingly found to be non-recombinogenic. This was the case
regardless of whether the strain was generated by inactivating
the three nucleases from an EcNR2 background, or by
reactivating exoX in nuc4
2; this suggests that the non-
recombinogenic phenotype did not arise from an off-target
mutation. Of the remaining strains, two showed a VPT4:VPT1
ratio similar to that of nuc4
2, while the strain containing xseA
(EcNR2.recJ
2,xonA
2,exoX
2) showed a ratio similar to that of
EcNR2. This suggests that ExoVII (xseA) may be the nuclease
responsible for the ability of EcNR2 to degrade phosphor-
othioated ends of dsDNA cassettes. An ExoVII single knockout
strain (EcNR2.xseA
2) was therefore generated.
Recombineering Properties of the ExoVII Mutant Strain
The VPT series of cassettes was recombined into EcNR2.xseA
2,
and recombination frequencies were calculated (Figure 1E). This
strain shows a pattern of relative frequencies similar to that of
nuc4
2: terminal phosphorothioation on the leading-targeting
strand is highly detrimental to recombination frequency, and has
impact equivalent to that of internal phosphorothioation
(Figure 1F–G). This suggests that these terminal PT bonds can
no longer be cleaved off, and therefore that ExoVII is the primary
E. coli nuclease responsible for degrading phosphorothioated ends
of dsDNA cassettes. Moreover, removing ExoVII significantly
increases the recombination frequency of unmodified dsDNA
(VPT1) above levels observed in EcNR2 (p=0.0076), suggesting
that the action of ExoVII on the ends of dsDNA cassettes may
compromise recombination frequency.
ExoVII is a nuclease encoded by the xseA and xseB genes [38]. It
is processive, and can degrade from either the 59 or 39 end [39].
While it is highly specific for ssDNA substrates, it is capable of
degrading short overhangs and then continuing into duplex
regions of DNA [39]. Its observed ability to degrade dsDNA ends
is likely due to strand ‘‘breathing,’’ possibly aided by endogenous
helicase enzymes, or by PT bonds lowering the annealing
temperature between the two strands [40]. Alternatively, another
endogenous 39-to-59 exonuclease may degrade part of the strand
complementary to the 59 PT bonds, leaving behind an ssDNA
overhang to which ExoVII can bind. While ExoVII is classified as
an exonuclease due to its requirement for a free ssDNA end, it
technically has endonucleolytic activity, given that its degradation
products are 4–12 bp oligonucleotides [39]. Thus, ExoVII likely
cleaves to the 39 end of the four 59 terminal PT bonds used in the
VPT cassette series, rather than degrading the PT bonds directly.
This explains the ability of ExoVII to readily process terminally
phosphorothioated cassettes.
Given that the action of ExoVII on the ends of dsDNA
cassettes appears to compromise recombination frequency, we
investigated whether its removal would increase the inheritance
of mutations encoded near the ends of the homology regions of a
dsDNA insertion cassette. Thus, we designed a non-phosphor-
othioated lacZ::kanR cassette with 2 bp mutations encoded 7 and
8 bp from both ends of the cassette. This construct was then
recombined into EcNR2 and EcNR2.xseA
2. KanR colonies were
selected, and their genotypes were analyzed at the mutation loci
(Figure 2A–B). The strain with ExoVII removed shows greater
inheritance of these end-located mutations (Figure 2A), although
the difference is only statistically significant for the mutation
encoded at the 39 end of the cassette (as defined with respect to
the lagging-targeting strand; Figure 2B, right panel). This
confirms that ExoVII also degrades non-phosphorothioated
dsDNA cassettes, and that it is partially responsible for the poor
inheritance of mutations located at the ends of such cassettes.
However, given that the EcNR2.xseA
2 strain still gives only low
levels of inheritance of these mutations, it is likely that other
endogenous nucleases are also responsible for degrading the ends
of dsDNA cassettes.
Because ExoVII is an ssDNA exonuclease [39], we next set out
to determine whether its removal has an ability to facilitate the
inheritance of end-located mutations in oligonucleotides as well as
dsDNA cassettes. We tested a 90mer oligonucleotide previously
designed to disrupt the lacZ gene [27], with seven premature stop
codons distributed along its sequence. This oligo was protected
with four PT bonds on each end. This ‘‘lacZ.7.stop’’ oligo was
recombined into three strains – EcNR2, EcNR2.xseA
2, and nuc5
2
(EcNR2.recJ,
2xonA
2,xseA
2,exoX
2,reda
2; Table 1), a strain with
Lambda Exo removed along with all four of the potent ssDNA
exonucleases. LacZ
2 colonies were identified by IPTG/X-Gal
screening, and lacZ was amplified from these clones for sequencing
analysis. From these sequences, it was determined which of the
seven mutations were inherited in a given clone, and the
proportion of recombinants with each mutation was thereby
calculated.
The results shown in Figure 2C–D suggest that nuc5
2 and
EcNR2.xseA
2 facilitate the inheritance of end-located mutations.
Nuc5
2 clones exhibited significantly more of the mutations
encoded by the lacZ.7.stop oligo (4.9460.20, **p=0.001,
Table 2. Identifying the Nuclease(s) which Degrade
Phosphorothioated Cassette Ends.
Strain Background VPT4:VPT1
EcNR2.xonA
2,recJ
2,exoX
2 (xseA
+) 0.77
EcNR2.xonA
2,xseA
2,exoX
2 (recJ
+) 0.06
EcNR2.recJ
2,xseA
2,exoX
2 (xonA
+) 0.09
EcNR2.xonA
2,recJ
2,xseA
2 (exoX
+) N/A
EcNR2 1.23
EcNR2.endA
2 1.55
EcNR2.xonA
2,recJ
2,xseA
2,exoX
2 (nuc4
2) 0.09
EcNR2.xseA
2 0.07
In order to determine which of the nucleases removed from nuc4
2 is
responsible for cleaving terminal PT bonds from dsDNA, four different strains
were created with only three of the four nuc4
2 nucleases inactivated. VPT1 and
VPT4 cassettes were recombined into all strains, and the ratio of number of
recombinants calculated. Only the strain containing functional xseA had nearly
as many VPT4 recombinants as VPT1 recombinants. This suggests that xseA
(ExoVII) is the nuclease responsible for cleaving PT bonds off the end(s) of VPT4,
thereby rendering the cassette recombinogenic. EcNR2.xonA
2,recJ
2,xseA
2 did
not give kanR recombinants for either cassette; this strain was recreated by
restoring exoX function in nuc4
2, whereupon it exhibited the same non-
recombinogenic phenotype. The biological basis of this phenotype is unclear.
VPT4:VPT1 ratios for EcNR2, EcNR2.endA
2, nuc4
2, and EcNR2.xseA
2 are also
shown for comparison.
doi:10.1371/journal.pone.0044638.t002
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enhanced inheritance of mutations at the 39 end of the 90mer
oligonucleotide (Figure 2D). Interestingly, removing ExoVII
phenocopies the performance of nuc5
2, leading to improved
mean conversions (4.8960.18, **p=0.004, Figure 2C) compared
to EcNR2, and no significant difference from nuc5
2 (p=0.8416).
Moreover, EcNR2.xseA
2 also provides for significantly greater
inheritance of mutations at the 39 end of the 90mer oligonucle-
otide (Figure 2D). Despite the dual polarity of ExoVII, its removal
has no apparent effect on the inheritance of 59 mutations, nor does
the removal of the other four exonucleases in nuc5
2. This suggests
that another unidentified nuclease may be responsible for
degrading the 59 ends of oligonucleotides. Such degradation may
be occurring postsynaptically, possibly mediated by the 59-to-39
exonuclease domain of polymerase I [41]. The 39 protection effect
of the ExoVII knockout strain is equivalent to that observed for the
nuc5
2 strain, suggesting that ExoVII is the only one of the five
removed exonucleases which compromises the inheritance of
mutations along the full length of phosphorothioated oligos.
Nuclease Knockouts Improve MAGE Performance
Given that ExoVII degrades oligonucleotides and may hinder
their ability to recombine, we investigated whether the removal of
ExoVII could improve oligonucleotide recombination frequency.
It has previously been shown [29] that removing the four potent E.
coli ssDNA exonucleases improves singleplex recombination
frequency, but only when low concentrations of oligo are used.
Since oligonucleotide concentration can easily be increased, this
has little practical benefit. However, nuclease removal may
provide a greater benefit when multiple oligonucleotides are
recombined simultaneously, as in MAGE [18]. Previous results
[28] have shown that the recombination frequency of a given oligo
is directly proportional to the mole fraction of that oligo in a
complex mixture, even when the oligo is present at concentrations
that would be saturating for singleplex oligo recombination. We
hypothesize that this apparent competition between oligonucleo-
tides is due to a limited number of oligos entering each cell during
electroporation. Thus, if several oligos are simultaneously co-
electroporated, the resulting intracellular concentration of any
Figure 2. Removal of ExoVII Preserves Mutation Inheritance. A) A non-phosphorothioated lacZ::kanR dsDNA cassette with two 2 bp sets of
mismatch mutations (placed 7&8 bp from each end of the cassette) was recombined into EcNR2 and EcNR2.xseA
2 cells. Resulting kanR recombinants
were then genotyped in order to determine whether they inherited these distally-located mutations. The distribution of mutations in EcNR2 (two
independent experiments, n=180) and EcNR2.xseA
2 (two independent experiments, n=177) was plotted as the frequency of clones inheriting 0
(empty black bars), 1 (hatched black bars), or 2 (filled black bars) sets of mutations. B) When the inheritance of each 2 bp mutation is considered
individually, both show increased preservation in EcNR2.xseA
2, although this is only statistically significant for the 2 bp mutation on the 39 end of the
cassette (as defined with respect to the lagging-targeting strand). Data are presented as the mean with the standard deviation from the mean. C&
D) A 90mer lagging strand-targeting oligonucleotide was designed to introduce 7 stop codons (placed at the +2, +23, +35, +49, +61, +73, +87 base
pair positions with respect to the 59 end) into the lacZ gene. This oligo was transformed into EcNR2, EcNR2.xseA
2, and nuc5
2 cells. LacZ
2 cells were
identified and their lacZ genes sequenced in order to determine which mutations were conferred in a given clone. The average total number of stop
codons introduced into a given clone is shown in C). Both EcNR2.xseA
2 (**p=0.0004, n=54) and nuc5
2 (**p=0.001, n=46) exhibit similar,
statistically significant increases in total mutation inheritance compared to EcNR2 controls (n=45). A breakdown of each strain’s inheritance of each
mutation is given in D). Both EcNR2.xseA
2 and nuc5
2 show similarly increased inheritance of 39-located mutations, but no increased inheritance of 59-
located mutations. No clones inherited the mutation encoded at position +2. Data in C) are presented as the mean with the standard error of the
mean.
doi:10.1371/journal.pone.0044638.g002
Improving Recombineering via Nuclease Removal
PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e44638given oligo will be low. Presynaptic nuclease degradation may
therefore have a large negative impact on recombination
frequency in MAGE.
To investigate this, we compared the MAGE performance of
EcNR2 and EcNR2.xseA
2. The nuc5
2 strain discussed previously
was also tested in order to determine if other exonucleases impact
MAGE performance. Lambda Exo was removed from this strain
along with the four potent ssDNA exonucleases, as Lambda Exo
has been shown [42] to have trace activity against ssDNA, and is
not required for oligo recombination. CoS-MAGE [28] was used
in these experiments, so as to determine whether the nuclease
knockout strains are able to improve upon the current best
practices for MAGE. Three different sets of 10 recombineering
oligos (each specifying a single TAGRTAA mutation, as
designed previously) [20] were tested, so as to ascertain the
MAGE performance of the strains at multiple loci, and in both
replichores. This was done in order to confirm the robustness of
the results, as oligo recombination frequency can vary due to
largely unelucidated oligo-specific and locus-specific effects [20].
Each of the three oligo sets was paired with a co-selection oligo
which restored the function of a nearby mutated antibiotic
resistance gene, thereby selecting for high recombination
frequency in the vicinity of the targeted loci. All recombineering
oligos had two PT bonds on each end, as was previously
optimized for MAGE [20]. Targeted loci were screened by
mascPCR [20] to determine which alleles were converted in a
given clone.
Results are shown in Figure 3. For all three recombineering
oligo sets (Sets 1–3 in Figure 3A–C, respectively), nuc5
2
significantly outperforms EcNR2 (***p,0.0001, ***p,0.0001,
*p=0.002, respectively). An average of 46% more alleles are
converted per clone in nuc5
2, and the frequency of clones with 5
or more conversions is increased by 200%. Furthermore, nuc5
2
reduces the frequency of clones with no conversions by 35%. All of
these improvements are particularly important given that MAGE
can be performed in iterative cycles, thereby compounding these
recombination enhancements. Thus, removing all potent ssDNA
exonucleases significantly improves the performance of CoS-
MAGE.
The EcNR2.xseA
2 strain appears to have properties interme-
diate between those of EcNR2 and nuc5
2. Although EcNR2.x-
seA
2 exhibits a statistically significant increase in MAGE
performance with Set 1 (1.4760.13) compared to EcNR2
(0.9660.07, **p=0.0001), this strain’s performance with Sets 2
& 3 was not statistically different from EcNR2 (p=0.7 & 0.2,
respectively). Given that Set 1 exhibited the largest difference in
performance between EcNR2 and nuc5
2 (65% higher allele
conversion in nuc5
2), it is possible that Set 1 is the most
susceptible to nuclease repression, and therefore that the effect of
removing ExoVII would be most apparent for this set. Overall,
using these three tested sets, nuc5
2 is superior to EcNR2.xseA
2.
This suggests that the action of ExoVII somewhat compromises
CoS-MAGE frequency, but that some or all of the other
exonucleases removed in nuc5
2 also have a role in oligo
degradation.
Examining the Effect of Phosphorothioate Bonds on
MAGE Frequency
As noted, the above experiments were performed with
recombineering oligonucleotides with two PT bonds on each
end. We next sought to determine whether the optimal number of
PT bonds was the same for each of our strains, whether the
benefits of nuc5
2 could be recapitulated simply by adding more
PT bonds to the recombineering oligos, and whether the
differences between the strains would be more pronounced if no
PT bonds were used. Thus, we recombined EcNR2 (Figure 4A),
EcNR2.xseA
2 (Figure 4B), and nuc5
2 (Figure 4C) with versions of
recombineering oligo Set 1, co-selected with a restoration oligo for
the nearby cat gene. A non-phosphorothioated version of oligo Set
1 was tested, as was a version with 4 PT bonds on each end. The
resulting allele conversion distributions were determined as above,
and compared with those previously observed for the version of
Set 1 with 2 PT bonds on each end.
The results are shown in Figure 4. Notably, for all tested
strains, the oligo set with 2 PT bonds gave the greatest average
number of allele conversions per clone. Comparatively, 4 PT
bonds had a detrimental effect on recombination frequency that
was most notable in nuc5
2 (Figure 4C), where the 0 PT set
(1.4460.12) outperformed the 4 PT set (1.0960.11, p=0.04).
Similarly, for EcNR2.xseA
2 (Figure 4B), the 2 PT set (1.4760.13)
exhibited a significant local optimum compared to the 0 PT set
(0.5260.08, ***p,0.0001) and the 4 PT set (1.0260.14,
*p=0.002), corroborating the detrimental effect of too many
PT bonds. Thus, the EcNR2.xseA
2 and nuc5
2 strains confer
recombineering advantages that cannot be recapitulated simply
by preventing nuclease degradation via the use of more PT
bonds. The detrimental effect of high levels of phosphorothioa-
tion may be due to PT bonds decreasing the strength of the
annealing interaction between the oligo and the lagging strand of
the replication fork [40]. Alternatively, oligos with PT bonds may
be somewhat toxic, thereby killing cells that take up a large
number of oligos and would otherwise yield many converted
alleles.
The relative performance of the differently phosphorothioated
oligo sets in the various strains suggests that this detrimental effect
of PT bonds is countervailed by the beneficial effect of nuclease
protection. In EcNR2 (Figure 4A), which has a full complement of
endogenous nucleases, the 4 PT set (0.8460.08) greatly outper-
forms the 0 PT set (0.4560.08, **p=0.0006), suggesting that the
effect of nuclease protection outweighs the detrimental impact of
the PT bonds on recombination frequency. Conversely, in nuc5
2
(Figure 4C), where nuclease degradation is mitigated by the
nuclease knockouts, the 0 PT set (1.4460.12) slightly outperforms
the 4 PT set (1.0960.11, p=0.04), suggesting that the detrimental
impact of the PT bonds outweighs any beneficial effect of nuclease
protection. In this strain, the 2 PT set (1.5860.10) is statistically
equivalent to the 0 PT set (1.4460.12, p=0.38), suggesting that
most or all relevant nuclease activity has been abrogated.
However, some level of residual exonuclease activity in nuc5
2 is
suggested by the strain’s poor inheritance of mutations encoded at
the 59 end of oligos (Figure 2D).
When no PT bonds are used to protect the recombineering
oligonucleotides, the nuc5
2 strain yields roughly threefold more
allele conversions per average clone than EcNR2. This stands to
reason, as non-PT oligos are likely to be particularly susceptible
to the activity of endogenous ssDNA exonucleases. Similarly,
EcNR2.xseA
2 also has low recombination frequency (roughly
similar to that of EcNR2) when 0 PT oligos are used. This
suggests that the exonucleases other than ExoVII (i.e. RecJ, Exo I,
ExoX, and Lambda Exo) are readily capable of degrading non-
protected oligos. However, when PT bonds are used, EcNR2.x-
seA
2 notably outperforms EcNR2, and is only slightly less
recombinogenic than nuc5
2 for this oligo set. In sum, these
results reinforce the importance of using phosphorothioated
oligos when performing MAGE in a strain containing endoge-
nous nucleases, but caution that the overuse of phosphorothioates
can be detrimental.
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The results described in this paper provide additional insight
into the cellular processes occurring during recombineering. First,
the discovery that ExoVII degrades the ends of dsDNA cassettes
solves the mystery of why dsDNA with both 59 ends phosphor-
othioated is still recombinogenic despite PT bonds blocking
Lambda Exo. Dually-phosphorothioated dsDNA enters the cell,
after which ExoVII degrades the 59 PT bonds of one or both
strands. This step may also require the action of a helicase or
another endogenous nuclease in order to generate ssDNA ends to
which ExoVII can bind. After the action of ExoVII, Lambda Exo
degrades the rest of the leading-targeting strand, leaving behind
the lagging-targeting ssDNA recombination intermediate [21,22].
Therefore, dually-phosphorothioated dsDNA recombines with a
frequency equal to or exceeding that of unmodified dsDNA
despite requiring the action of one or more endogenous nucleases
in addition to Lambda Exo. This suggests that there is a great deal
of interaction between endogenous nucleases and recombineering
cassettes. The variable dsDNA recombination frequencies exhib-
ited in this study by nuclease knockout strains support this notion.
For example, the nuc4
2 strain exhibits decreased recombination
frequency for all tested VPT cassettes. The origin of this
phenotype is uncertain; it is possible that one of the removed
exonucleases has a role in dsDNA recombination, or that the
presence of exogenous linear dsDNA is somewhat toxic to cells
with these four nucleases removed, thereby selecting against cells
which take up the cassettes necessary for recombination. Along
similar lines, strain EcNR2.recJ
2,xonA
2,xseA
2 appears to be non-
recombinogenic, for reasons that are unclear, while EcNR2.xseA
2
has slightly enhanced recombination frequency for cassettes
without PT bonds blocking the leading-targeting strand.. Taken
together, this suggests that modifying endogenous nuclease activity
may be a powerful lever for affecting Lambda Red recombination,
Figure 3. Effect of Nuclease Genotype on CoS-MAGE Performance. CoS-MAGE was carried out in three strains (EcNR2, EcNR2.xseA
2, and
nuc5
2), using sets of ten oligos encoding TAGTAA mutations, and a co-selection oligo designed to revert a mutated selectable marker located within
500 kb of the targeted loci. Set 1 (A) was co-selected with chloramphenicol acetyltransferase (cat, inserted at the mutS locus). In comparison with
EcNR2 (n=319), both EcNR2.xseA
2 (**p=0.0001, n=135) and nuc5
2 (***p,0.0001, n=257) show statistically significant increases in mean oligo
conversion, a decreased proportion of clones exhibiting no allele conversions, and more clones with 5+ conversions. Set 2 (B) was co-selected with
beta lactamase (bla, inserted with the l prophage). Here, nuc5
2 (n=142) shows a statistically significant increase in recombineering performance
compared to both EcNR2 (***p,0.0001, n=268) and EcNR2.xseA
2 (***p,0.0001, n=184). Set 3 (C) was co-selected with tolC. Here, nuc5
2 (n=139)
shows a statistically significant increase in mean allele conversion compared to EcNR2 (*p=0.002, n=327). EcNR2.xseA
2 (n=92) shows an
intermediate phenotype between EcNR2 (p=0.2) and nuc5- (p=0.3). All oligos used in this experiment had two PT bonds on both ends. Data shown
in the right panels are presented as the mean with the standard error of the mean. Statistical significance is denoted using a starred system where ns
denotes a non-significant variation, * denotes p,0.003, ** denotes p,0.001, and *** denotes p,0.0001.
doi:10.1371/journal.pone.0044638.g003
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ments of dsDNA recombination frequency.
The VPT series recombination frequency data for EcNR2
(Figure 1C) also further supports the recently proposed dsDNA
recombineering mechanism involving a full-length ssDNA inter-
mediate [21,22]. Other proposed mechanisms [24,31] have
suggested an intermediate in which the 59 ends of both homology
regions have been recessed by Lambda Exo, leaving behind the
dsDNA heterology region flanked by 39 homology ssDNA
overhangs. These proposed mechanisms have different implica-
tions on the expected recombination frequencies of certain VPT
series cassettes. According to the recently proposed mechanism,
VPT7 would be expected to have a recombination frequency
significantly less than that of unmodified dsDNA, as PT bonds
between the 59 homology and heterology regions of both strands
would prevent Lambda Exo from degrading one strand and
generating a full-length ssDNA intermediate. In contrast, the
placement of PT bonds in VPT7 would be expected to facilitate
Lambda Exo’s generation of the 39 overhang intermediate
suggested in the other proposed mechanisms. Thus, if this
mechanism were correct, VPT7 would be expected to have equal
or greater recombination frequency than unmodified dsDNA. As
shown in Figure 1C and Table S2, VPT7 has 10.2-fold lower
recombination frequency than unmodified dsDNA (VPT1) in
EcNR2. This result is consistent with those from similar previous
experiments [22,43], supporting the proposed mechanism involv-
ing a full-length ssDNA intermediate, and further refuting the
previously proposed mechanisms.
This work also lends more insight into recombineering with
oligonucleotides. We have shown that removing selected endog-
enous nucleases improves multiplex recombination frequency,
despite the use of a high total concentration (5.2 mM) of oligos.
This suggests that the concentration of any given oligo within the
cell is not enough to overcome the action of endogenous nucleases,
and therefore that oligo entry into the cell is a limiting factor in
MAGE. This observation initially appears to contradict the
conclusion presented in a recent study by Sawitzke et al. [29],
which showed that the recombination frequency of a given
oligonucleotide could be increased by the addition of non-specific
carrier oligos which prevent endogenous exonucleases from
Figure 4. Effect of Phosphorothioate Bonds on CoS-MAGE Performance. The effect of oligo phosphorothioation on the CoS-MAGE
performance of the various nuclease knockout strains was studied. Variants of recombineering oligo Set 1 (described in Figure 3) with no PT bonds (0
PT) and four PT bonds on both ends (4 PT) were compared with the initial version of Set 1, which had two PT bonds on both ends (2 PT).
Recombination was performed with cat co-selection as prior. For EcNR2 (A), n=133 (0 PT), n=319 (2 PT), n=186 (4 PT). For EcNR2.xseA
2 (B), n=94 (0
PT), n=92 (2 PT), n=86 (4 PT). For nuc5
2 (C), n=132 (0 PT), n=257 (2 PT), n=183 (4 PT). Data shown in the right panels are presented as the mean
with the standard error of the mean. Statistical significance is denoted using a starred system where ns denotes a non-significant variation, * denotes
p,0.003, ** denotes p,0.001, and *** denotes p,0.0001.
doi:10.1371/journal.pone.0044638.g004
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was tested only for very low concentrations of the recombinogenic
oligo (up to 0.01 mM). Even at this concentration, adding carrier
oligos (at 0.1 mM) had less than a 2-fold enhancement of
recombination frequency; a more pronounced enhancement was
observed only for very low concentrations of recombinogenic oligo
(0.001 mM and below). In concentration regimes typical for
MAGE (.1 mM total oligos), it has been shown that adding a
second oligonucleotide decreases the recombination frequency of the
first oligonucleotide [28]. Presumably, at these concentrations
(which have been previously been shown to be optimal for
recombination frequency [18] and were therefore used in this
work) any benefit conferred by the saturation of endogenous
exonucleases is outweighed by competition for cellular entry.
These findings therefore suggest that enhancing oligo uptake is
likely to be a fruitful avenue for further improving MAGE.
Additionally, studying the consequences of different levels of
oligo phosphorothioation in the EcNR2, EcNR2.xseA
2 and nuc5
2
strains enabled the deconvolution of the countervailing effects of
phosphorothioation. Phosphorothioate bonds improve recombi-
nation frequency by protecting oligos against nuclease degrada-
tion, but also hinder recombination frequency – possibly by
reducing the strength of the annealing interaction between the
oligo and the lagging strand of the replication fork, or by causing
toxicity to the cell. Two PT bonds on both ends of recombineering
oligonucleotides was found to be optimal for all three strains tested
in this work, but future nuclease knockout strains will need to be
optimized in order to determine the ideal number of PT bonds for
oligos recombined into that strain.
Beyond providing additional mechanistic insight into Lambda
Red recombination, this work also achieves several important
improvements of oligo and dsDNA recombineering. Firstly,
removing ExoVII was shown to improve the inheritance of
mutations at the 39 ends of oligonucleotides and dsDNA cassettes.
This may be particularly useful in oligonucleotide recombineering,
as it allows more mutations to be reliably introduced by a single
oligo. This could be leveraged for several applications, such as
simultaneously modifying several residues near the active site of a
protein, recoding [20] a larger region with a given oligonucleotide,
or modifying several genetic features (e.g. promoter strength,
ribosome binding site strength, and the presence or absence of a
premature stop codon) with a single oligo. Similarly, the
improvement of MAGE recombination frequency via the use of
EcNR2.xseA
2 and nuc5
2 will also have substantial utility. These
strains facilitate greater modification of a population of cells in a
single MAGE cycle (or in multiple cycles), which will be useful for
projects that seek the rapid allelic diversification of a population of
cells [18]. Such advancements are also expected to be useful for
improving the Red-mediated diversification of BACs and
plasmids. Similarly, the enhanced recombination frequency of
these strains also means that fewer cycles will be needed in order to
achieve an isogenic recoded population of cells, or to identify a
strain with all desired genetic changes among a set of screened
clones.
Finally, this work provides guidelines as to the appropriate
strain to use for a given recombineering application. It should be
noted that the nuc5
2 strain was observed to have poor regrowth
after electroporation, taking roughly twice as long as EcNR2 or
EcNR2.xseA
2 to recover to confluence. The pre-electroporation
growth rate of nuc5
2 was only slightly less than those of EcNR2
and EcNR2.xseA
2 (150 minutes vs. 125 minutes to reach mid-log
growth phase from a 1:100 dilution of overnight culture), likely
due to the ability of mutS removal to suppress the known cold-
sensitive growth phenotype of recJ/xonA/xseA/exoX quadruple
mutants [44]. Therefore, while nuc5
2 has somewhat better
multiplex recombination frequency than EcNR2.xseA
2, its poor
regrowth properties cause each recombination cycle to take
notably longer. Thus, using EcNR2.xseA
2 is likely optimal for
applications in which multiple cycles are necessary; the nuc5
2
strain may be preferable for applications in which a single cycle is
sufficient and fast regrowth is not necessary. While quadruple
mutants for recJ, xonA, xseA, and exoX have increased point
mutation rates, this phenomenon is epistatic to mutS [44]. Given
that strains used for genome engineering are often mutS
2,
removing these nucleases (as in nuc5
2) does not further exacerbate
the mutator phenotype. However, the combined removal of xonA,
recJ, and exoX has been shown to increase rates of rearrangement
mutations involving repetitive sequences [45], and therefore this
strain should not be used for applications in which genomic
stability is paramount. Directed evolution and/or the restoration
of selected nucleases may facilitate improved growth rates and
genomic stability, without substantially compromising recombina-
tion frequency. This may be a valuable avenue for future study.
In conclusion, this work helps elucidate how endogenous
nucleases act on ssDNA and dsDNA cassettes used for recombi-
neering. In addition to providing further mechanistic insight into
Lambda Red recombination, this work also facilitated the creation
of nuclease knockout strains with markedly improved recombina-
tion frequency and mutation inheritance. These strains will be
highly useful as chassis in future recombineering efforts, and may
enable new and powerful applications of Lambda Red technology.
Materials and Methods
A full list of primers and recombineering oligonucleotides used
in this work is presented in Table S1. All oligonucleotides were
ordered from Integrated DNA Technologies with standard
purification and desalting.
Generating dsDNA Recombineering Cassettes
Both the VPT series of dsDNA recombineering cassettes
described above and the lacZ::kanR cassette with mutations
encoded in its homology arms were generated by PCR using the
primers denoted in Table S1. PCRs were performed using Kapa
HiFi HotStart ReadyMix, with primer concentrations of 0.5 mM,
and 0.1 ng of lacZ::kanR dsDNA (generated in previous work [21])
used as template. PCRs had a total volume of 50 mL, and were
heat activated at 95uC for 5 min, then cycled 30 times with a
denaturation temperature of 98uC (20 sec), an annealing
temperature of 62uC (15 sec), and an extension temperature of
72uC (45 sec). PCRs were brought to 72uC for 5 min, and then
held at 4uC. PCR products were cleaned with the Qiagen PCR
purification kit (elution in 50 mLH 2O). Samples were desalted
with MicroconH Ultracel YM-100 columns (spinning twice at 500
6g for 20 min, and bringing to 500 mLi nH 2O before each spin).
Resulting samples were then brought to 100 mLi nH 2O and
quantitated on a NanoDrop
TM ND1000 spectrophotometer. All
samples were analyzed on a 1% agarose/EtBr gel to confirm that
the expected band was present and pure.
In vitro dsDNA Digestion by Lambda Exo
LacZ::kanR dsDNA (20 ng) with zero, one, or both ends
phosphorothioated (VPT1, VPT2, and VPT4, respectively; see
Figure 1A) was added to 9 mL of 1X Lambda Exonuclease Buffer
(New England Biolabs). Lambda Exonuclease (New England
Biolabs) was serially diluted in 1X Lambda Exonuclease Buffer as
needed and 1 mL was then added to the reaction. Reactions were
incubated at 37uC for 30 min, heat inactivated at 75uC for
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denaturing PAGE gel (180 V, 40 min, post-stained in Invitrogen
SYBR Gold for 15 min).
Strain Creation
EcNR2 (Escherichia coli MG1655 DmutS::cat D(ybhB-
bioAB)::[lcI857 N(cro-ea59)::tetR-bla]) [18] was used as the basis
for all strains created in this work. From an EcNR2 background,
nuclease genes endA, xonA, recJ, xseA, exoX, and reda (Lambda Exo)
were inactivated singly or in combination (as described in the
Results section) via oligo-mediated Lambda Red recombination as
described below. Knockout oligos (Table S1) were designed to
introduce a premature stop codon and a frameshift mutation at the
beginning of the nuclease gene, thereby rendering the targeted
nuclease inactive. Strains used for CoS-MAGE were generated by
recombining an oligonucleotide designed to inactivate a chromo-
somal resistance marker (cat, tolC,o rbla) and identifying resulting
colonies with the appropriate sensitivity to antibiotic or SDS [46].
Performing Lambda Red Recombination
Lambda Red recombinations with ssDNA and dsDNA were
performed as previously described [18,21]. In brief, cultures were
grown in LB Lennox media (10 g tryptone, 5 g yeast extract, 5 g
NaCl per 1 L water), from a 1:100 dilution of an overnight culture.
Cultures were placed in a rotator drum at 30uC until they reached
an OD600 of 0.4–0.6 (typically 2.25–2.5 hrs). Lambda Red
expression was then induced by shaking cultures at 300 rpm in
a4 2 uC water bath (15 min). Induced cultures were immediately
cooled on ice, and 1 mL of cells were washed twice in ice cold
deionized water (dH2O). The cell pellet was resuspended in 50 mL
of dH2O containing the intended recombineering construct(s). For
experiments in which dsDNA cassettes were recombined, 100 ng
was used. For experiments in which a single oligonucleotide was
recombined, 1 mM of oligo was used. For experiments in which
sets of ten recombineering oligos were recombined along with a
co-selection oligo, 0.5 mM of each recombineering oligo was used,
along with 0.2 mM of the co-selection oligo (5.2 mM total).
Samples were electroporated (BioRad GenePulser
TM, 0.1 cm
cuvette, 1.78 kV, 200 V,2 5 mF), and allowed to recover in
3 mL LB Lennox in a rotator drum at 30uC. Cultures were
recovered for at least 3 hours (5+ hours in CoS-MAGE
experiments, so as to eliminate polyclonal colonies), and then
plated and analyzed as below.
Analyzing Recombination
In order to analyze the recombination of lacZ::kanR insertion
cassettes, recovery cultures were plated onto LB Lennox plates
with kanamycin sulfate (30 mg/mL), incubated at 30uC overnight,
and the number of resulting colonies counted. To determine the
total number of cells present, recovery cultures were diluted and
plated onto LB Lennox plates with carbenicillin (50 mg/mL).
These results were used to determine the recombination frequency
of a given sample (# recombinants/# total cells), or the ratio of
the number of kanR recombinants yielded by two different
cassettes in a given strain. All platings were performed in
duplicate.
Allele-specific colony PCR (ascPCR) or multiplex allele-specific
colony PCR (mascPCR) [20] was used to detect the 1–2 bp
mutations generated in the CoS-MAGE experiments, the inacti-
vation of endogenous nucleases, and the recombination of the
lacZ::kanR cassette with mutations encoded in its homology arms.
In these experiments, two PCRs are performed for each tested
clone – one with a forward primer designed to hybridize to the
wild type sequence at a locus targeted by a recombineering
cassette, and one with a forward primer designed to hybridize to
the mutated sequence conferred by the recombineering cassette;
the same reverse primer is used in both reactions. If the mutant-
detecting PCR gives a band but the wild type detecting PCR does
not, the clone is scored as a recombinant. In mascPCR, primer sets
for interrogating several wild type or mutant loci are combined in
a single reaction, and each amplicon has a different size ranging
from 100 bp to 850 bp. Singleplex ascPCR reactions (used to
determine whether a given nuclease had been inactivated) were
performed with Kapa 2GFast HotStart ReadyMix including 10X
Kapa dye. PCR reactions had a total volume of 20 mL, with
0.5 mM of each primer, and a template of 1 mL of stationary phase
culture derived from a given clone. These PCRs were carried out
with an initial activation step at 95uC for 2 min, then cycled 30
times with a denaturation temperature of 95uC (15 sec), an
annealing temperature of 63–67uC (15 sec; temperature as
optimized for a given pair of ascPCR reactions), an extension
temperature of 72uC (40 sec), and a final extension at 72uC for 90
sec.
CoS-MAGE recovery cultures were plated on media selective
for the co-selected resistance marker (LB Lennox with 50 mg/mL
carbenicillin for bla,2 0mg/mL chloramphenicol for cat, or 0.005%
SDS for tolC, with 20 mg/mL chloramphenicol added to enhance
the robustness of selection), and targeted loci in the resulting clones
were screened by mascPCR using Kapa 2GFast Multiplex PCR
ReadyMix with 10X Kapa dye. PCRs to detect the two mutations
encoded in the homology arms of the lacZ::kanR cassette were also
performed in multiplex, as were PCRs to simultaneously genotype
several nuclease knockout mutations. Monoclonal colonies were
grown to stationary phase under proper antibiotic selection, and
PCR template was prepared by diluting 2 uL of culture into
100 uL of dH2O. These mascPCR reactions had a total volume of
10 mL, with 0.2 mM of each primer and 2 mL of template. These
PCRs were carried out with an initial activation step at 95uC for
3 min, then cycled 26 times with a denaturation temperature of
95uC (15 sec), an annealing temperature of 63–67uC (30 sec;
temperature as optimized for a given pair of mascPCR reactions),
an extension temperature of 72uC (1 min), and a final extension at
72uC for 5 min. All ascPCRs and mascPCRs were analyzed on
1.5% agarose/EtBr gels (180 V, 60 min).
We repeated recombination experiments with the mutation-
encoding lacZ::kanR cassette twice for EcNR2 and EcNR2.xseA
2.
In each experiment, 96 individual colonies were genotyped for
each strain. Only monoclonal and unambiguous mascPCR results
were counted towards the final analysis presented here. 59 and 39
mutation inheritance data points were each combined and
analyzed for statistically significant differences between strains
using the Mann-Whitney U-test with significance defined as
p,0.05.
In CoS-MAGE experiments, all strains were recombined with
all oligo sets at least twice. Replicates were combined to generate a
complete data set for each strain’s performance with each set of
oligos. At least 96 colonies were genotyped for each strain tested
with each recombineering oligo set. Only monoclonal and
unambiguous mascPCR results were counted toward the final
analysis presented here. Given the large sample sizes tested here (n
.85), we used parametric one way ANOVA to test for significant
variance in the CoS-MAGE performance of the strains (EcNR2,
EcNR2.xseA
2, nuc5
2) for a given oligo set. Subsequently, we used
a Student’s t-test to make pairwise comparisons with significance
defined as p,0.05/n, where n is the number of pairwise
comparisons. Here, n=15, as these data were planned and
collected as part of a larger set with 6 different strains, although
only the results for EcNR2, EcNR2.xseA
2, and nuc5
2 are
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the analyses presented in Figures 3 & 4. Statistical significance in
Figures 3 & 4 are denoted using a system where * denotes
p,0.003, ** denotes p,0.001, and *** denotes p,0.0001. For the
experiment in which oligo sets were tested with 0, 2, or 4 PTs on
both ends, comparisons were made between EcNR2, EcNR2.x-
seA
2, and nuc5
2 (the only three tested strains in this experiment)
for each of the three differently phosphorothioated oligo sets,
separately. Additionally, comparisons were made between each
oligo set for each of the three strains, also separately. Thus, 15
pairwise comparisons were performed, and significance thresholds
are as above.
For the experiment in which a lacZ-inactivating oligo with 7 stop
codons (lacZ.7.stop) was recombined, recombinants were identi-
fied as white colonies on plates containing Fisher ChromoMax
TM
IPTG/X-Gal solution, and recombination frequencies (# of white
colonies/total # of colonies) were determined for every replicate.
For the white colonies, the entire lacZ open reading frame was
amplified with primers lacZ.seq-f and lacZ.seq-2-r (Table S1),
using Kapa HiFi HotStart ReadyMix and the same conditions as
described above for this enzyme. Samples were then purified with
the Qiagen PCR purification kit, also as described above, and
quantitated on a NanoDrop
TM ND1000 spectrophotometer.
Purified DNA was submitted to Genewiz for Sanger sequencing
(40 ng DNA, with 25 pmol of either lacZ.seq-f or lacZ.seq-2-r
primer). Good quality sequence pairs were stitched together using
SeqMan (Lasergene DNAstar) and exported as FASTA sequences.
These sequences were then analyzed for their genotype at the loci
where the lacZ.7.stop oligo could impart inheritance of mutations.
The recombinations and recombination frequency counts were
repeated thrice so as to ensure consistency, but sequencing was
only performed on one biological replicate. Mean allele conversion
metrics were generated from the sequencing data by scoring each
mutation locus as 1 for a mutant sequence or 0 for a wild type
sequence. We tested for statistically significant variance in mean
allele conversions using a parametric one way ANOVA. Subse-
quently, we used a Student’s t-test to make pairwise comparisons
with significance defined as p,0.05/3, i.e. p,0.01. Statistical
significance in Figure 2C is denoted using a starred system where *
denotes p,0.01, ** denotes p,0.001, and *** denotes p,0.0001.
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